Navigation Links
Algeta Demonstrates Targeted Cancer-killing Potential of Novel,Alpha Particle Linked Antibodies in Leading Medical Journal Blood

Preclinical Studies Show 227Th-rituximab More Effective at Killing CD20-Positive Lymphoma Cells Than 90Y-tiuxetan-ibritumomab (Zevalin)

OSLO, Norway, 14 June 2007 - Algeta ASA (OSE: ALGETA), the Norwegian cancer therapeutics company, announces that a research paper showing the potential of its TH-1 technology for targeted cancer therapy has been published by the leading medical journal, Blood, the official journal of the American Society of Hematology (ASH).

Algeta's TH-1 technology links Thorium-227, which emits alpha particles, to cancer-targeting molecules such as antibodies. Alpha-emitting radionuclides are of considerable interest in the treatment of cancer as they are highly destructive to tumour cells but have very short range. Linking this radionuclide to tumour-seeking molecules creates a conjugate with the potential to specifically seek and destroy cancers while leaving surrounding healthy tissues undamaged.

The Blood paper describes how researchers from the Norwegian Radium Hospital (Oslo) in collaboration with Professor Oliver Press at the Fred Hutchison Cancer Research Center (Seattle, USA) and Algeta have linked Thorium-227 to the monoclonal antibody rituximab to create 227Th-rituximab and demonstrated its potent anti-tumour effects.

Rituximab binds to a specific molecule on the cancer cell surface called CD20 and is marketed in USA as Rituxan® by Genentech and Biogen-Idec for the treatment of certain types of non-Hodgkin's lymphoma (NHL) and rheumatoid arthritis, and as MabThera® by Roche for the treatment of certain types of NHL. Rituximab-based therapies generated global sales of nearly $6 billion in 2006.

In in vitro studies 227Th-rituximab killed CD20-positive lymphoma cells at low doses (Bq/ml) while in preclinical models, a single injection of 227Th-rituximab induced complete tumor regression in up to 60% of tumours without apparent toxicity.

<
'"/>




Page: 1 2 3 4

Related medicine technology :

1. Algeta to Present Phase II Clinical Study Data for Alpharadin in Prostate Cancer at ASCO
2. The International Myeloma Foundation Says Data Reported at a Global Medical Meeting in Greece Demonstrates Improved Survival for a Wide Range of Myeloma Patients
3. Publication on Pixantrone Preclinical Studies Demonstrates Reduced Cardiotoxicity Compared to Equiactive Doses of Doxorubicin and Mitoxantrone
4. New Research Demonstrates Broad Efficacy of Azixa (MPC-6827) Against Multiple Tumor Types and in Drug Resistant Cell Lines
5. Gerons Telomerase Inhibitor Cancer Drug Demonstrates Good Pharmacokinetics and Tolerability in Phase I/II Trial
6. Frova Phase III Study Data Demonstrates That Short-Term Prevention Treatment Reduces Frequency and Severity of Menstrual Migraine
7. Mymetics HIV Vaccine Demonstrates First-Ever Production of Neutralizing IgA Antibodies in Non-Human Primate Model
8. Newly Published Data Demonstrates Superiority of Cipralex Over Duloxetine for Acute Treatment of Depression
9. Introgens Advexin Demonstrates Clinical Benefit in Inherited Cancer
10. Prostate Cancer: Clinical Study Demonstrates Superior Efficacy of Docetaxel Chemotherapy
11. Lpath Demonstrates First-in-Class AMD Results With Its Lead Drug Candidate, Sphingomab
Post Your Comments:
(Date:9/3/2015)... Research and Markets ( http://www.researchandmarkets.com/research/84p6xc/investigation ) ... on China,s Bromhexine Market, 2010-2019" report to their ... of respiratory disease keeps growing and so does the ... of vasicine, is a mucolytic agent used in the ... or excessive mucus. It can make the phlegm thinner ...
(Date:9/3/2015)... , Sept. 3, 2015  CVS Health Corporation ... Merlo , the company,s president and chief executive officer, ... chief financial officer, will be speaking to investors at ... 17, 2015. They are scheduled to speak at approximately ... the presentation will be broadcast simultaneously through the Investor ...
(Date:9/3/2015)... 03, 2015 Research and ... the "Investigation Report on China Oxiracetam Market, 2010-2019" ... derivative of pyrrolidone, was first synthesized by ISF in ... and injection entered the Italian market respectively in 1987 ... China , annual sales rising from ...
Breaking Medicine Technology:China Bromhexine Market Report 2015-2019 2Investigation Report on China's Oxiracetam Market, 2010-2019 2
(Date:9/3/2015)... ... September 03, 2015 , ... Topical BioMedics, Inc., ... destination of his six-month, 10,000 mile journey from Santiago, Chile to Times Square ... calls the “Connecting Las Americas” project—Max crossed six countries in 168 days on ...
(Date:9/3/2015)... ... September 03, 2015 , ... Real Time Pain Relief ... professional bull rider David Mason has signed an official endorsement deal with the company. ... of six and his first bull at 15. He is an Australian bull riding ...
(Date:9/3/2015)... PEACHTREE CITY, GA (PRWEB) , ... September 03, ... ... does not cover the cost of graduated compression garments. However, graduated compression garments ... management. , Wound care and lymphedema specialist, Robyn Bjork, was recently sponsored by ...
(Date:9/3/2015)... ... September 03, 2015 , ... The first part of ... allegations made by IVC filter lawsuits filed against Bard.** These lawsuits, filed ... a Bard IVC filter broke or failed, have recently been consolidated for pretrial proceedings ...
(Date:9/3/2015)... ... September 03, 2015 , ... ... comprehensive eating disorder treatment for adults and adolescents struggling with anorexia, bulimia, ... has joined the medical treatment team. As a Staff Psychiatrist, Dr. Calinoiu ...
Breaking Medicine News(10 mins):Health News:Topical BioMedics Announces Visit from Max Wohlgemuth Kitslaar, Ending his Six-Month, 10,000 Mile Journey from Chile to New York on a 1976 Moto Guzzi Motorcycle 2Health News:Topical BioMedics Announces Visit from Max Wohlgemuth Kitslaar, Ending his Six-Month, 10,000 Mile Journey from Chile to New York on a 1976 Moto Guzzi Motorcycle 3Health News:Topical BioMedics Announces Visit from Max Wohlgemuth Kitslaar, Ending his Six-Month, 10,000 Mile Journey from Chile to New York on a 1976 Moto Guzzi Motorcycle 4Health News:Topical BioMedics Announces Visit from Max Wohlgemuth Kitslaar, Ending his Six-Month, 10,000 Mile Journey from Chile to New York on a 1976 Moto Guzzi Motorcycle 5Health News:Topical BioMedics Announces Visit from Max Wohlgemuth Kitslaar, Ending his Six-Month, 10,000 Mile Journey from Chile to New York on a 1976 Moto Guzzi Motorcycle 6Health News:Real Time Pain Relief Sponsors the Talented PBR Bull Rider from Down Under - David Mason 2Health News:Real Time Pain Relief Sponsors the Talented PBR Bull Rider from Down Under - David Mason 3Health News:SIGVARIS Supports the Lymphedema Treatment Act to Help Patients with Lymphedema 2Health News:SIGVARIS Supports the Lymphedema Treatment Act to Help Patients with Lymphedema 3Health News:Bard IVC Lawsuit Allegations Reach National Prime Time News 2Health News:Bard IVC Lawsuit Allegations Reach National Prime Time News 3Health News:Ileana Calinoiu, MD Joins Eating Recovery Center of Washington Medical Treatment Team 2Health News:Ileana Calinoiu, MD Joins Eating Recovery Center of Washington Medical Treatment Team 3
... ... 100 Attorneys in New England - Result of Peer-review Process , , ... Boston, MA (PRWEB) December 9, 2009 -- Boston medical malpractice ... named among the "Top 100" lawyers in New England for 2009 as listed by Super Lawyers ...
... Beverly ... Face Institute, to The Big Apple. A world famous rhinoplasty and facelift surgeon as featured ... East Coast and West Coast patients. , ... Rancho Cucamonga, CA (PRWEB) December 9, 2009 -- Southern California facial plastic ...
... , March of Dimes Polls Moms On Their ... 9 Moms worry. Even before they become moms. From the minute they ... the birth, moms worry. , Will my baby be healthy? Will I ... I eat? , The March of Dimes polled about 1,200 moms to ...
... Dec. 8 Beckman Coulter, Inc. (NYSE: BEC ... simplify, automate, and innovate complex biomedical tests, will host its ... Thursday, December 17, 2009, from 2:30 p.m. to 5:00 p.m. ... Charlie Slacik, chief financial officer, and other corporate executives will ...
... ... , ... (PRWEB) December 8, 2009 -- Many parents dread the holiday season as they struggle ... parents worried and isolated. Rather than celebrating the holiday season, parents are concerned ...
... Healthcare consultant partners with Laguna Honda Hospital ... Health , SAN FRANCISCO, Dec. 8 ... on a new 11-month contract with The City and County ... model of care and organizational effectiveness development program for the ...
Cached Medicine News:Health News:Andrew C. Meyer, Jr. and Robert M. Higgins Named Top 100 New England Super Lawyers 2Health News:Dr. 90210 Rhinoplasty Specialist Now Accommodates Both the East and West Coast 2Health News:Sushi & Breastfeeding Join Birth Defects & Preterm Birth as Leading Concerns of Moms 2Health News:Beckman Coulter to Host Annual Business Review 2Health News:Book Offers Help for Parents Struggling with Difficult Teens During the Upcoming Holidays 2Health News:Lumetra Healthcare Solutions Begins Contract With City and County of San Francisco 2Health News:Lumetra Healthcare Solutions Begins Contract With City and County of San Francisco 3
Nucleus divider with 1.25 mm tip and blade offset at a 60 degree angle is ideal for performing the "Phaco Chop" technique to be used in left hand. Round knurled handle....
Flat 7 mm wide hook. Flat serrated handle with polished finish. Overall length: 5.1 inches....
#2 10 mm hook. Flat serrated handle with polished finish. Overall length: 5.5 inches....
Small bulbous tip with flat sides. Flat serrated handle with polished finish. Overall length: 5.1 inches....
Medicine Products: